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Introduction
Metastatic epidural spinal cord compression (MESCC) is
a debilitating and common complication of cancer,
occurring in 5–14% of cancer patients. More than 20 000
new cases are reported every year in the USA.1,2 Acute
onset of MESCC needs immediate treatment.3,4 Standard
treatment for MESCC consists of corticosteroids and
radiotherapy,3,4 with which only about 50% of patients
are able to walk and few non-ambulatory patients ever
walk again.1–9 The role of surgery in the management of
MESCC has not been established. Before radiation
became available, surgery (in the form of simple
laminectomy) was the only treatment. With the
introduction of radiotherapy, results with laminectomy
plus radiation did not seem to differ from results with
radiation alone. Surgical treatment was largely
abandoned when several retrospective studies5–10 and a
small randomised trial11 did not show any beneﬁt for
laminectomy alone or in combination with radiotherapy.
However, laminectomy might not be the best operation
for MESCC. Most spinal metastases causing MESCC are
located in the vertebral body, anterior to the spinal
cord.1,2 Laminectomy involves the removal of posterior
elements of the spinal column and does not remove
tumour, and thus often does not result in immediate
decompression. Furthermore, the procedure can cause
destabilisation of the spine because often only the
posterior elements are intact and removal of these
elements causes instability.
In the 1980s, another type of surgical procedure was
developed for the treatment of MESCC. The tumour was
removed and immediate circumferential decompression
was achieved, usually through an anterior approach.
When needed, reconstruction of the spine
intraoperatively was possible to provide immediate
stabilisation. Several uncontrolled surgical series12–16 and
a meta-analysis17 reported that direct decompressive
surgery, with or without postoperative radiotherapy, was
superior to radiation alone. However, these non-
randomised studies were subject to patient selection
bias, heterogeneous tumour types, unclear inclusion
criteria, and imprecise endpoints. Consequently, these
studies have not established direct decompressive
surgery as an effective treatment. To determine the value
of surgery in the management of MESCC, we undertook
a randomised trial comparing the efﬁcacy of direct
decompressive surgery plus postoperative radiotherapy
with that of radiotherapy alone. 
Methods
Patients
Patients at least 18 years old with a tissue-proven
diagnosis of cancer (not of CNS or spinal column origin)
and MRI evidence of MESCC were eligible for the study.
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Summary
Background The standard treatment for spinal cord compression caused by metastatic cancer is corticosteroids and
radiotherapy. The role of surgery has not been established. We assessed the efﬁcacy of direct decompressive surgery.
Methods In this randomised, multi-institutional, non-blinded trial, we randomly assigned patients with spinal cord
compression caused by metastatic cancer to either surgery followed by radiotherapy (n=50) or radiotherapy alone
(n=51). Radiotherapy for both treatment groups was given in ten 3 Gy fractions. The primary endpoint was the ability
to walk. Secondary endpoints were urinary continence, muscle strength and functional status, the need for
corticosteroids and opioid analgesics, and survival time. All analyses were by intention to treat.
Findings After an interim analysis the study was stopped because the criterion of a predetermined early stopping rule
was met. Thus, 123 patients were assessed for eligibility before the study closed and 101 were randomised.
Signiﬁcantly more patients in the surgery group (42/50, 84%) than in the radiotherapy group (29/51, 57%) were able
to walk after treatment (odds ratio 6·2 [95% CI 2·0–19·8] p=0·001). Patients treated with surgery also retained the
ability to walk signiﬁcantly longer than did those with radiotherapy alone (median 122 days vs 13 days, p=0·003).
32 patients entered the study unable to walk; signiﬁcantly more patients in the surgery group regained the ability to
walk than patients in the radiation group (10/16 [62%] vs 3/16 [19%], p=0·01). The need for corticosteroids and
opioid analgesics was signiﬁcantly reduced in the surgical group.
Interpretation Direct decompressive surgery plus postoperative radiotherapy is superior to treatment with
radiotherapy alone for patients with spinal cord compression caused by metastatic cancer.
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MESCC was deﬁned radiographically as a true
displacement of the spinal cord (by an epidural mass)
from its normal position in the spinal canal. Patients
also had to have at least one neurological sign or
symptom (including pain) and not have been totally
paraplegic for longer than 48 h before study entry. The
MESCC had to be restricted to a single area, which could
include several contiguous spinal or vertebral segments.
Patients with a mass that compressed only the cauda
equina or spinal roots were excluded. Those with
multiple discrete compressive lesions were also excluded
(unless they had one area of compression and multiple
non-compressive lesions). Patients with certain
radiosensitive tumours (lymphomas, leukaemia,
multiple myeloma, and germ-cell tumours) were
excluded, as were patients with pre-existing or
concomitant neurological problems not related directly
to their MESCC (eg, brain metastases). Additionally,
patients with previous MESCC and those who had
received spinal radiation such that they were unable to
receive the study dose were excluded. Patients also had
to have a general medical status good enough to be
acceptable surgical candidates and an expected survival
of at least 3 months. 
The study was approved by the institutional review
boards of the University of Kentucky and other
participating institutions, and written informed consent
was obtained from all patients before study entry.
Procedures
The study was a randomised, multi-institutional, non-
blinded trial with two treatment groups. Before
randomisation, all patients had imaging of the entire
spinal cord. The imaging technique consisted of MRI
with whole spine sagittal T1 and T2 imaging and axial T1
imaging. Additional MRI techniques were used as
clinically appropriate. There was a central review of all
MRI scans for conﬁrmation of MESCC.
When diagnosed, all patients were given 100 mg
dexamethasone immediately, then 24 mg every 6 h until
the start of radiotherapy or surgery. Corticosteroids were
then reduced and continued until completion of
radiotherapy. Patients with severe diabetes or other
relative contraindications to high-dose corticosteroids
were treated with reduced doses when appropriate.
Before randomisation, patients were stratiﬁed
according to treating institution, tumour type, ambulatory
status, and relative stability of the spine. Spinal stability
was ascertained according to Cybulski’s guidelines.18
Patients with pathological spine fractures or evidence of
bone in the spinal canal were also judged to have spinal
instability. Randomisation within strata by permutated
blocks was done separately at each institution with a
computerised technique, which ensured immediate
randomisation at study entry. The study was undertaken
by the Bluegrass Neuro-Oncology Consortium with seven
participating institutions (University of Kentucky
[n=70 patients], MD Anderson [n=14], Brown University
[n=12], University of Alabama-Birmingham [n=2],
University of Michigan [n=1], University of Pittsburgh
[n=1], University of South Florida [n=1]). 
For patients randomised to the radiation group,
radiotherapy was started within 24 h after
randomisation. The total dose was 30 Gy given in ten
fractions (3·0 Gy10 fractions). Treatments were
delivered to a port that encompassed one vertebral body
above and below the visible lesion. There was a central
review of radiotherapy treatment plans to monitor
protocol compliance. Patients allocated to surgery were
operated on within 24 h after randomisation. The
protocol did not specify operative techniques or ﬁxation
devices. However, the aim of surgery was to provide
immediate direct circumferential decompression of the
spinal cord. The operation was tailored for each patient
depending on the level of the spine involved and the
patient’s circumstances. In general, for anteriorly-
located tumours the approach in the cervical spine was
anterior, and in the thoracic and lumbar spine,
depending on the tumour location, the approach was
through a transversectomy or anterior approach. For
laterally-located tumours, a lateral approach was used,
and for posteriorly-located tumours, a laminectomy was
done and any other posterior elements involved were
removed. Stabilisation of tumours in all locations was
performed if spinal instability was present; cement
(methyl methacrylate), metallic rods, bone grafting, or
other ﬁxation devices were used. Within 1 month of
treatment Phillip Tibbs reviewed operative reports and
William Regine reviewed plans for post-surgery
radiotherapy to monitor protocol compliance. Patients
were given radiotherapy, as in the radiation group,
within 14 days after surgery. Steroids were given on the
same schedule for both groups.
Patients had neurological assessments before
treatment, weekly during radiotherapy, and within 1 day
after completion of treatment. Patients then had regular
study follow-up assessments every 4 weeks until the end
of the trial or death. Patients were also reassessed at any
time they had symptoms suggestive of neurological
progression.
The primary endpoint of the study was the ability to
walk after treatment. A patient was deemed ambulatory
if he or she could take at least two steps with each foot
unassisted (4 steps total), even if a cane or walker was
needed. We assessed ambulatory status in two ways, and
both methods were prespeciﬁed. The combined
ambulatory rate was the percentage of patients who
maintained or regained the ability to walk immediately
after completion of radiotherapy and quantiﬁed the
initial success rate of treatment. Ambulatory time after
treatment was a measure of long-term success.
Secondary endpoints were urinary continence, changes
in Frankel functional scale scores19 and American Spinal
Injury Association (ASIA) motor scores,20 and use of
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corticosteroids and opioid analgesics. Corticosteroid use
was assessed by calculating and comparing mean daily
dexamethasone equivalent doses. Pain relief was
assessed by calculating and comparing mean daily
morphine equivalent doses. Survival time after treat-
ment was also recorded. All time dependent endpoints
were measured from the day of randomisation until
death or last follow up.
Statistical analysis
Results from previous uncontrolled studies have
suggested that the expected combined post-treatment
ambulatory rate in patients treated with radiation alone is
about 45%,1–9 and uncontrolled surgical series, in which
direct decompressive surgery was used, reported
post-treatment ambulatory rates of about 75%.12–16 These
studies suggest that the advantage from surgery is an
additional 30% increase in the post-treatment ambulatory
rate compared with radiation alone. To determine sample
size for this study, we used a more conservative expected
difference in post-ambulatory rate between study groups
of 20%. With this assumption and with 100 patients in
each treatment group, the chance of achieving overall
statistically signiﬁcant results at the p0·05 level, using a
two-sided test, was 82%.21 The study design also included
provision for an interim analysis to be done at the halfway
point (after 100 patients were entered into the trial)
according to the O’Brien-Fleming rule.22
An intention-to-treat analysis was used throughout.
Multivariate analyses were based on a Cox regression
model.23 The covariates used were treatment group, age,
sex, primary tumour type, spinal level involved,
predominant position of metastasis in vertebra, stability
of spine, Frankel and ASIA scores at study entry, length
of time motor symptoms associated with cord
compression were present before treatment, and length
of time between diagnosis of the primary tumour and
development of cord compression. All these analyses
were prespeciﬁed. 
Role of the funding source
The sponsor had no role in study design, data collection,
data analysis, data interpretation, or the writing of the
report. The corresponding author had full access to all
the data in the study and had ﬁnal responsibility for the
decision to submit for publication.
Results
We compared combined ambulatory rates after
treatment between the two groups using a Cochran-
Mantel-Haenszel statistic based on ambulatory status.
This comparison yielded a p value of 0·001, which fell
below the predetermined signiﬁcance level for early
termination of the trial according to the O’Brien
Fleming rule (p0·0054). Because of proven superiority
of surgical treatment, the data safety and monitoring
committee deemed the trial should be stopped early.
Between Sept 1, 1992, and Dec 31, 2002, 123 patients
were assessed for eligibility and, of these, 101 were
entered into the trial before it closed (ﬁgure 1). Protocol
violations occurred with ﬁve patients. In the surgery
group, three patients did not receive postoperative
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Radiation group (n=51) Surgery group (n=50)
Men/women 37/14 33/17       
Median age, years  60  60       
Primary tumours
Lung 13 13   
Breast  6  7   
Prostate 10 9
Other genitourinary 6 5   
Gastrointestinal 4  2   
Melanoma 3  3   
Head and neck 2  1   
Unknown 3  5   
Other  4  5
Walking at entry 35 34
Continent at entry 32 30
Median Frankel score at entry D D
Median ASIA score at entry 90 89
Spinal level of compression
Cervical  5  8   
T1-T6 18 20   
T7-T12 28 22
Position of spinal tumour
Anterior 33 28   
Lateral 11  9   
Posterior  7 13
Unstable spine  18 20
Median time between diagnosis of primary tumour 7 months  3 months  
and development of MESCC
Median time between development of motor 12 days 10 days  
symptoms and treatment of MESCC  
D=ambulatory but with neurological symptoms.
Table 1: Baseline characteristics of study patients
123 assessed
         for eligibility
0 lost to follow-up
4 no or incomplete
    postoperative
    radiotherapy
0 lost to follow-up
1 treated intially
    with surgery
22 excluded
   9 did not meet
       inclusion criteria
   5 refused to participate
   8 physician refusal
50 surgery group 51 radiation group
50 analysed 51 analysed
101 randomised
Figure 1: Trial proﬁle
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radiotherapy and a fourth patient stopped radiotherapy
before receiving the complete course. In the radiation
group, one patient was treated with surgery as well as
postoperative radiotherapy. Table 1 shows baseline
characteristics of patients entered in the study. Overall
median follow-up times were 102 days (IQR 0–1940) in
the surgery group and 93 days (0–1117 days) in the
radiation group (p=0·10).
The combined post-treatment ambulatory rate in the
surgery group was 84% (42/50) and 57% (29/51) in the
radiation group. Ambulatory rates were compared
between the two groups using a Cochran-Mantel-
Haenszel statistic after stratifying by pretreatment
ambulatory status. This analysis yielded a p value of
0·001 with an odds ratio of 6·2 (95% CI 2·0–19·8).
Patients in the surgery group retained the ability to walk
for signiﬁcantly longer than did those in the radiation
group (median 122 days vs 13 days, p=0·003; ﬁgure 2).
Multivariate analysis showed surgery (p=0·0017) and
pretreatment Frankel score (p=0·0008) to be associated
with longer ambulatory time.
In the subgroup of patients who could walk at study
entry, 94% (32/34) in the surgery group continued to
walk after treatment compared with 74% (26/35) in the
radiation group (p=0·024). Patients in the surgical group
were able to walk for a median of 153 days compared
with 54 days in the radiation group (odds ratio 1·82
[95% CI 1·08–3·12] p=0·024; ﬁgure 3). Multivariate
analysis showed surgery (p=0·0048), Frankel score
(p=0·016), and breast primary tumour (p=0·029) to be
associated with longer ambulatory times.
32 patients (16 in each group) entered the study unable
to walk; of these, ten patients (62%) in the surgery group
regained the ability to walk compared with three patients
(19%) in the radiation group (p=0·012). Additionally,
non-ambulatory patients treated with surgery walked for
a median of 59 days compared with a median of 0 days
for patients in the radiation group (p=0·04).
Surgical treatment resulted in signiﬁcant differences
in maintenance of continence, muscle strength (ASIA
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Radiation group Surgery group Relative risk* 95% CI* P* Signiﬁcant predictors**
(n=51) median  (n=50) median
Maintenance of continence 17 days 156 days 0·47 0·25–0·87 0·016 Surgery RR=0·51 (0·29–0·90)
Baseline Frankel Score RR=0·56 (0·3–0·73)
Maintenance of ASIA score 72 days 566 days 0·28 0·13–0·61 0·001 Surgery RR=0·30 (0·14–0·62) 
Stable Spine RR=0·43 (0·22–0·83)
Cervical Spinal Level RR=0·49 (0·26–0·90)
Baseline Frankel Score RR=0·65 (0·46–0·91)
Maintenance of Frankel score 72 days 566 days 0·24 0·11–0·54 0·0006 Surgery RR=0·26 (0·12–0·54)
Stable Spine RR=0·39 (0·20–0·75) 
Cervical Spinal Level RR=0·53 (0·74–0·98)
Baseline Frankel Score RR=0·62 (0·44–0·88)
Survival time 100 days 126 days 0·60 0·38–0·96 0·033 Surgery RR=0·60 (0·40–0·92) 
Breast Primary Tumour RR=0·29 (0·13–0·62)
Lower Thoracic Spinal Level RR=0·65 (0·43–0·99)  
*Based on a Cox model with all covariates included. **Based on a Cox model with only signiﬁcant predictors included (stepwise selection).
Table 2: Secondary endpoints
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Figure 2: Kaplan–Meier estimates of length of time all study patients remained ambulatory after treatment
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Figure 3: Kaplan–Meier estimates of length of time patients who were ambulatory at study entry remained
ambulatory after treatment
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scores), functional ability (Frankel scores), and increased
survival time (table 2). The surgical group also had a
substantial reduction in use of corticosteroids and opioid
analgesics. In the surgery group, the median mean daily
dexamethasone equivalent dose was 1·6 mg
(IQR 0·1–44·0) compared with 4·2 mg (0·0–50·0) in
the radiation group (p=0·0093). In the surgery group,
the median mean daily morphine equivalent dose was
0·4 mg (0·0–60·0) compared with 4·8 mg (0·0–200·0)
in the radiation group (p=0·002).
The 30-day mortality rates were 6% in the surgery
group and 14% in the radiation group (p=0·32). 30-day
morbidity rates were calculated by deterioration in ASIA
and Frankel scores. At 30 days, surgery group patients
maintained or improved their pretreatment ASIA
muscle strength scores at a signiﬁcantly (p=0·0064)
higher rate than did patients in the radiation group (86%
vs 60%). Also, at day 30 after treatment, the percentage of
patients with Frankel scores at or above study entry level
was signiﬁcantly (p=0·0008) higher in the surgery group
than in the radiation group (91% vs 61%). Surgery did
not result in prolonged hospitalisation; the median
hospital stay was 10 days in both the surgery group (IQR
2–51 days) and the radiation group (0–41 days; p=0·86).
Extended hospital stays (greater than 20 days) occurred
in seven patients in the surgery group and 11 in the
radiation group.
Ten patients in the radiation group (20%) had a
substantial decline in motor strength during
radiotherapy and crossed over to receive surgery. The
primary tumour histologies of these crossover patients
were: lung (four), gastrointestinal (two), prostate (one),
other genitourinary (two), sarcoma (one). At the time of
surgery, none of these patients could walk. Three (30%)
regained the ability to walk. Of the crossover patients,
four (40%) had surgical complications consisting of
three wound infections and one failure of ﬁxation that
needed additional surgery.
Discussion
This prospective randomised trial shows that patients
with MESCC treated with direct decompressive surgery
plus postoperative radiotherapy retain the ability to walk
for longer and regain the ability more often than do
patients treated with radiotherapy alone. Surgery allows
most patients to remain ambulatory for the remainder of
their lives, whereas patients treated with radiation alone
spend a substantial proportion of their remaining time
paraplegic. Surgical treatment also results in increased
survival time. The better survival time in the surgical
group was probably because a greater proportion of
patients in this group were ambulatory and remained so
for longer than those in the radiation group. Therefore,
patients in the surgery group were less susceptible to
infections, blood clots, and other problems that result in
the death of paraplegic patients. Surgical treatment also
reduces the need for corticosteroids and opioid pain relief.
The cause of damage to the spinal cord from
compression is complex and multifactorial, although
two mechanisms predominate.1,2 Direct compression
results in oedema, venous congestion, and
demyelination. If the compression is of short duration,
the effects are reversible; remyelination and recovery of
function is possible. However, with prolonged
compression, secondary vascular injury occurs with
infarction of the spinal cord. After this type of injury, no
meaningful recovery is possible. Surgical
decompression is immediate, whereas radiotherapy
takes several days to have an effect. Surgery was
probably able to provide relief from compression before
irreversible vascular injury occurred in a substantial
number of patients in our study. Thus a higher
percentage of patients were able to recover function in
this treatment group, which explains the number of
patients who regained the ability to walk after treatment
and the initial success of the treatment. The fact that
surgery preserved the ability to walk much longer than
did radiation is because of the ability of surgery to
remove tumour. In patients treated with radiation alone,
tumour was left behind and regrowth with secondary
compression was more likely. 
With any surgical procedure, operative mortality and
morbidity have to be weighed against any possible
beneﬁt from surgery. Surprisingly, surgery did not
result in an increase in length of hospital stay. 30-day
mortality rates did not differ signiﬁcantly between the
two groups, and 30-day morbidity was substantially
worse in the radiation group. Therefore, there was no
excess mortality or morbidity due to surgery.
A possible limitation of the study was patient selection
bias. Any study that has exclusion criteria selects a
subset of the total number of patients with a disease for
study. Our study was designed to reﬂect the way patients
with MESCC were being treated routinely in community
and academic medical centres. The patient population
studied consisted of those patients for whom surgery
would be regarded as a realistic treatment option.
Patients with very radiosensitive tumours, multiple
areas of spinal cord compression, or total paraplegia for
longer than 48 h were excluded. Therefore, the results of
this trial cannot be used to justify surgery in all patients
with MESCC and apply only to patients comparable to
those included in our study. Even in this group of
patients, reasonable clinical judgment should be used in
the selection of patients for surgery.
Our trial shows that surgery is an effective treatment
for MESCC, but should surgery be the initial treatment
for all patients similar to those in the study who have
operable lesions? An argument could be made that
ambulatory patients should be treated with radiation
ﬁrst, and surgery reserved for those patients who
progress. This approach would reduce the number of
surgeries done and might be as effective. However, the
results of our trial do not lend support to the use of
www.thelancet.com Vol 366   August 20, 2005 647
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radiation alone as ﬁrst-line treatment. In the subgroup
of patients who were ambulatory at the start of therapy,
initial treatment with surgery was signiﬁcantly better at
preserving the ability to walk. Further evidence comes
from the radiation patients who crossed over to surgery.
These patients were treated initially with radiation and
then operated on when they failed radiation and lost the
ability to walk. In these patients, only 30% regained the
ability to walk. This result compares unfavourably with
the 62% post-treatment ambulatory rate of the patients
who were originally not able to walk and received
surgery as their ﬁrst treatment. Clearly, ﬁrst-line
treatment with surgery was superior. For these reasons,
the best treatment for spinal cord compression caused
by metastatic cancer is surgery as initial treatment
followed by radiotherapy.
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